TY - JOUR
T1 - Deprescribing
T2 - What is the gold standard? Themes that characterized the discussions at the first Danish symposium on evidence-based deprescribing
AU - Kaas Oldenburg, Lykke I
AU - Dalin, Dagmar
AU - Drastrup, Anne Mette
AU - Vermehren, Charlotte
N1 - © 2022 The Authors.
PY - 2022/4/21
Y1 - 2022/4/21
N2 - The first Danish symposium on evidence-based deprescribing was held in September 2019. The symposium aimed to increase the awareness of deprescribing in general, to discuss the importance of deprescribing, and, thus, a potential consensus on key issues on a national deprescribing agenda. The invited keynote speaker, Barbara Farrell, from the Bruyére Research Institute, Ottawa, Canada, presented their thorough work on deprescribing guideline development and application. The symposium consisted of two parts: Part 1 concentrated on establishing the need for deprescribing in our society. Part 2 consisted of a panel debate that put the practical application and implementation of deprescribing in perspective to the input from the audience and the structure of the Danish healthcare system. The panelists represented key stakeholders, e.g., clinical pharmacists, general practitioners, hospital doctors, Danish Health Authority representatives, health politicians concerning deprescribing in Denmark. The event allowed 145 participants to discuss the importance of implementing deprescribing in a Danish setting. This commentary highlights and discusses the major themes that characterized the symposium: "why deprescribe?", "deprescribing research" and a theme dedicated to "problems of concern." The emergence of these themes formed the basis for the discussion of new strategies and a proposal for a future gold standard to succeed in deprescribing.
AB - The first Danish symposium on evidence-based deprescribing was held in September 2019. The symposium aimed to increase the awareness of deprescribing in general, to discuss the importance of deprescribing, and, thus, a potential consensus on key issues on a national deprescribing agenda. The invited keynote speaker, Barbara Farrell, from the Bruyére Research Institute, Ottawa, Canada, presented their thorough work on deprescribing guideline development and application. The symposium consisted of two parts: Part 1 concentrated on establishing the need for deprescribing in our society. Part 2 consisted of a panel debate that put the practical application and implementation of deprescribing in perspective to the input from the audience and the structure of the Danish healthcare system. The panelists represented key stakeholders, e.g., clinical pharmacists, general practitioners, hospital doctors, Danish Health Authority representatives, health politicians concerning deprescribing in Denmark. The event allowed 145 participants to discuss the importance of implementing deprescribing in a Danish setting. This commentary highlights and discusses the major themes that characterized the symposium: "why deprescribe?", "deprescribing research" and a theme dedicated to "problems of concern." The emergence of these themes formed the basis for the discussion of new strategies and a proposal for a future gold standard to succeed in deprescribing.
UR - http://www.scopus.com/inward/record.url?scp=85148560342&partnerID=8YFLogxK
U2 - 10.1016/j.rcsop.2022.100102
DO - 10.1016/j.rcsop.2022.100102
M3 - Journal article
C2 - 35478500
SN - 2667-2766
VL - 5
SP - 1
EP - 12
JO - Exploratory Research in Clinical and Social Pharmacy
JF - Exploratory Research in Clinical and Social Pharmacy
M1 - 100102
ER -